Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles.

Autor:	Vanrusselt H; Aligos Belgium BV , Leuven, Belgium., Kum DB; Aligos Belgium BV , Leuven, Belgium.; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Taverniti V; Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR S1110, Université de Strasbourg , Strasbourg, France., Liu C; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Acosta Sanchez A; Novalix , Leuven, Belgium., Corthout N; VIB Bio-imaging Core , Leuven, Belgium., Munck S; VIB Bio-imaging Core , Leuven, Belgium., Baumert TF; Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR S1110, Université de Strasbourg , Strasbourg, France.; Service d'Hépato-gastroenterologie, Pôle Hépato-digestif, IHU Strasbourg, Strasbourg University Hospitals , Strasbourg, France., Beigelman L; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Blatt LM; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Symons JA; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Deval J; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Raboisson P; Aligos Belgium BV , Leuven, Belgium., Verrier ER; Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR S1110, Université de Strasbourg , Strasbourg, France., Jekle A; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Vendeville S; Aligos Belgium BV , Leuven, Belgium., Debing Y; Aligos Belgium BV , Leuven, Belgium.
Jazyk:	angličtina
Zdroj:	Journal of virology [J Virol] 2023 Oct 31; Vol. 97 (10), pp. e0072223. Date of Electronic Publication: 2023 Sep 27.
DOI:	10.1128/jvi.00722-23
Abstrakt:	Importance: Chronic hepatitis B is the most important cause of liver cancer worldwide and affects more than 290 million people. Current treatments are mostly suppressive and rarely lead to a cure. Therefore, there is a need for novel and curative drugs that target the host or the causative agent, hepatitis B virus itself. Capsid assembly modulators are an interesting class of antiviral molecules that may one day become part of curative treatment regimens for chronic hepatitis B. Here we explore the characteristics of a particularly interesting subclass of capsid assembly modulators. These so-called non-HAP CAM-As have intriguing properties in cell culture but also clear virus-infected cells from the mouse liver in a gradual and sustained way. We believe they represent a considerable improvement over previously reported molecules and may one day be part of curative treatment combinations for chronic hepatitis B. Competing Interests: H.V., D.K.B., C.L., A.A.S., L.B., L.M.B., J.A.S., J.D., P.R., A.J., S.V., and Y.D. are or were directly or indirectly employed by Aligos Therapeutics and may own stock. V.T., N.C., S.M., T.F.B., and E.R.V. declare no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu